1. [1] Albanell, J., Baselga, J. (2000): Systemic therapy emergencies. Semin. Oncol. 27: 347-361.
2. [2] Baldwin, J.R., Phillips, B.A., Overmyer, S.K., Hatfield, N.Z., Narang, P.K. (1992): Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. Cancer Chemother. Pharmacol. 30: 433-438.
3. [3] Bowers, D.G., Jr., Lynch, J.B. (1978): Adriamycin extravasation. Plast. Reconstr. Surg. 61: 86-92.
4. [4] Chun, R., Garret, L.D., Vail, D.M. (2007): Doxorubicin. In: Small Animal Clinical Oncology, 4thed (Withrow SL. and Vail DM., eds), pp. 178-179, Saunders, St. Louis.
5. [5] Conde-Estvez, D., Mateu-de, A. J. (2014): Treatment of anthracycline extravasation using dexrazoxane. Clin. Transl. Oncol. 16: 11-17.